Back to News
Market Impact: 0.42
Dyne Reports One-Year Z-Basivarsen Data Showing Functional Improvements In DM1
Source: Nasdaq
Healthcare & Biotech
Dyne Therapeutics reported additional one-year Phase 1/2 ACHIEVE trial data for investigational Z-basivarsen, showing sustained functional improvements across multiple measures in patients with myotonic dystrophy type 1. The durable clinical-data update is a positive de-risking event for the company’s neuromuscular disease pipeline and could support investor confidence in the program.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.58
Ticker Sentiment
DYN0.78
More News
- PHC Holdings surge to near 4-year high after Toho takeover proposal confirmed
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- Walgreens owner nears $9 billion deal to sell Boots chain- WSJ
- Why is Toho stock volatile today?
- Lilly’s Foundayo shows cardiovascular safety in diabetes trial
- Nvidia is approaching a breakout level. Plus, what we want to see from Micron